Advanced Biomed Inc.

Advanced Biomed Inc. is a healthcare company focused on developing microfluidic biochip technologies for oncology applications, particularly in circulating tumor cell (CTC) detection and analysis. The company's product portfolio includes automated systems and diagnostic chips designed to identify and characterize different types of circulating tumor cells from blood samples. Its core devices include the A+Pre automated sample preparation system, the AC-1000 rare cell detection device, the A+SCDrop single-cell capture device, and the A+CellScan analyzer. The company also manufactures immunochromogenic kits—including the A+CTCE, A+CTCM, A+EMT, and A+CM kits—that use antibody-based detection to identify specific cancer cell populations and tumor-associated macrophages.

Revenue streams derive from the sale of microfluidic biochips and assay products and services to cancer patients and healthcare providers. The company is developing A+LCGuard for early lung cancer screening. Beyond its core diagnostic business, Advanced Biomed operates medical clinics in mainland China.

The company operates with a small employee base of 31 full-time staff and maintains headquarters in New York, New York, while conducting research and development and commercializing products primarily in Taiwan and China. The company was incorporated in Nevada and founded in 2014.